超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

瑞典Cellectricon 
瑞典Cellectricon公司成立于2000年.是一家領先的細胞篩選產品的生產商
Dynaflow 系統是一種作用于離子通道受體和安全藥理測試的藥物篩查和最優化工具，它創下了銷售記錄。微流控分析芯片系統現在正被大量的關鍵公司使用，它得到了全球12家最佳制藥公司中的10家公司的確認。

Cellectricon captures the emerging paradigm shift in drug discovery towards microfluidic assays and the products are designed to enable substantial productivity increases with maximized efficiency, data quality, throughput and analytical precision. Cellectricon's unique approach of combining microfluidics engineering with biology has enabled the development of completely new types of miniaturized real time cell-based screening devices for applications in biotechnology, biomedical research and drug discovery.

The company has successfully launched two products up to date with strong customer validation. Ten out of twelve big pharma companies has already adopted the first product the Dynaflow? System for ion channel drug discovery. In December 2005 the company launched their second product line, Cellaxess?, highly-efficient & easy-to-use electroporation systems for transfection of adherent cells.

Cellectricon has a solid scientific foundation in comprehensive research results that act as the starting point for the business. Today, the company holds a solid patent portfolio in a variety of areas such as electrophysiology, microfluidics, microfabrication, and electroporation. Cellectricon's product and project portfolio is protected by more than 15 patents and patent applications of which several are first in their respective field.

The company has a highly promising product pipeline addressing several high growth markets within cell biology. Future areas include broad cell assay coverage for drug screening and clinical areas such as Cloning, IVF & Gene manipulation.

Owners

Cellectricon is a privately held company. The main shareholders are InnovationsKapital, Investor Growth Capital, and Karolinska Investment Fund, together with employees and seed investors.

Founders

Cellectricon was founded in late 2000 based on ten years of internationally renowned research and an extensive and solid patent portfolio by:

Dr. Daniel T. Chiu, Assistant Professor of Chemistry at the University of Washington, Seattle.

Jakob Lindberg, Former CEO at Cellectricon (2000-2004). Prior to his position at Cellectricon AB, Jakob Lindberg worked as a consultant at McKinsey & Co.

Dr. Owe Orwar , Professor at the Department of Physical Chemistry at Chalmers University of Technology, Gothenburg.